Correvio might look for buyer after FDA panel shoots down heart drug

在 FDA 的专家小组下了心药后, Correvio 可能会寻找买家

2019-12-12 12:20:24 pharmamanufacturing


Correvio Pharma Corp could hunt for a potential buyer now that its pivotal heart drug is not likely to win FDA approval.  Earlier this week, an FDA expert advisory panel failed to recommend approval of Cerrevio’s treatment for trial fibrillation called Brinavess. The panel said the drug could pose serious side effects. The FDA is not required to follow the panel’s advice, but it usually does. News of the FDA setback sent shares for Correvio tumbling and now the company is exploring alternatives. Correvio, which has about 138 employees, said it has teamed up with Piper Jaffray, an investment and asset management firm, to explore its options. The company said it may also streamline its North America operations but did not specify if such a move would involve job cuts. Read the full Reuters report. /* Create two equal columns that floats next to each other */ .column1 { float: left; width: 35%; padding: 10px; } .column2 { float: right; width: 65%; padding: 10px 20px; } /* Clear floats after the columns */ .row:after { content: ""; display: table; clear: both; } /* Responsive layout - makes the two columns stack on top of each other instead of next to each other */ @media screen and (max-width: 600px) { .column1 { width: 100%; } .column2 { width: 100%; } } label { color: #000000; font-size: 14px; } input[type=text] { width: 100%; padding: 5px 20px; margin: 10px 0; box-sizing: border-box; border: 1px solid #cccccc; color: #868383; } input[type=email] { width: 100%; padding: 5px 20px; margin: 10px 0; box-sizing: border-box; border: 1px solid #cccccc; color: #868383; } select{ width: 100%; padding: 3px 20px; margin: 10px 0; border: 1px solid #cccccc; color: #868383; } input[type=submit] { padding: 10px 20px; margin: 10px 0; box-sizing: border-box; border: 1px solid #cccccc; font-size: 18px; background-color: #f40c00; color: #ffffff; font-weight: bold; display: block; margin: auto; width: 50%; }
由于其关键的心脏药物不太可能获得 FDA 的批准, CorvioPharma Corp 可能会寻找潜在买家。 本周早些时候, FDA 专家顾问小组未能建议批准 Cerrevo 的治疗纤颤的试验,称为 Brinaviess 。该小组说,这种药物可能会产生严重的副作用。FDA 不需要遵循委员会的建议,但通常是这样做的。 FDA 受挫的消息导致该公司股价暴跌,现在该公司正在寻找替代方案。拥有约138名员工的 Corvio 表示,已与投资和资产管理公司 Piper Jaffray 合作,探讨其选择。该公司表示,可能还会精简北美业务,但没有具体说明此举是否涉及裁员。 阅读路透社的完整报告。 /*创建两个相互浮动的相等列*/。collen1{ float : left ;宽度:35%;填充:10px ;}coln2{} float : right ;宽度:65%;填充:10px20px ;}/*列后的 clear */。行:在{ content :"" display : table ; clear : two ;}/* Responsive 布局之后,将两列堆栈放在一起,而不是隔壁*/@ media 屏幕和(最大宽度:600px ){。专栏1{宽度:100%;}专栏2{宽度:100%;}标签{颜色:#000000;字体大小:14px ;}输入[类型=文本]{宽度:100%;填充:5px 20px ;边距:10px 0;框大小:边框;边框:1px 固体# cccccc ;颜色:#868383;}输入[类型=电子邮件]{宽度:100%;填充:5px 20px ;边框: px 大小:1个框;边框:1 px 固体# cccc ;颜色:#8683;}